Expertise in
2
conditions

Dr. Thomas Marbury

Nephrology
Orlando Clinical Research Center
5055 S Orange Ave, 
Orlando, FL 
Expertise in
2
conditions
Orlando Clinical Research Center
5055 S Orange Ave, 
Orlando, FL 

Overview

Thomas Marbury is a Nephrologist in Orlando, Florida. Dr. Marbury is highly rated in 2 conditions, according to our data. His top areas of expertise are Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Low Sodium Level, and Small Lymphocytic Lymphoma (SLL).

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 35 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Nephrology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Orlando Clinical Research Center
5055 S Orange Ave, Orlando, FL 32809

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials

A Phase 1, Open Label, Nonrandomized, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 in Subjects With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
A Phase 1, Open Label, Nonrandomized, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 in Subjects With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Enrollment Status: Completed
Publish Date: December 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
Pharmacokinetics of Imlunestrant in Participants With Hepatic Impairment
Pharmacokinetics of Imlunestrant in Participants With Hepatic Impairment
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants.
A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants.
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function
A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function
Enrollment Status: Completed
Publish Date: May 30, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Pharmacokinetic Study of KW-6356 in Subjects With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
A Pharmacokinetic Study of KW-6356 in Subjects With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Enrollment Status: Completed
Publish Date: April 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants With Moderate or Mild Hepatic Impairment and Normal Hepatic Function
Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants With Moderate or Mild Hepatic Impairment and Normal Hepatic Function
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
An Open Label, Single Arm, Single Dose Study to Evaluate the Pharmacokinetics and Safety and Tolerability of MGTA 145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
An Open Label, Single Arm, Single Dose Study to Evaluate the Pharmacokinetics and Safety and Tolerability of MGTA 145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
Enrollment Status: Completed
Publish Date: January 11, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Pilot Safety and Pharmacokinetic Study of MB-102 Versus Iohexol and the Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
A Pilot Safety and Pharmacokinetic Study of MB-102 Versus Iohexol and the Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Enrollment Status: Completed
Publish Date: October 26, 2023
Intervention Type: Drug, Device
Study Drugs: MB-102, Iohexol
Study Phase: Phase 2
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
Enrollment Status: Completed
Publish Date: March 24, 2023
Intervention Type: Drug
Study Phase: Phase 1
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Enrollment Status: Completed
Publish Date: March 23, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of Surufatinib
A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of Surufatinib
Enrollment Status: Completed
Publish Date: November 03, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Fruquintinib
An Open-Label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Fruquintinib
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of GSK3228836 in Adults With Hepatic Impairment and Healthy Matched Control Participants (B-Assured)
A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of GSK3228836 in Adults With Hepatic Impairment and Healthy Matched Control Participants (B-Assured)
Enrollment Status: Completed
Publish Date: September 27, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study To Assess The Effect Of Hepatic Impairment On The Pharmacokinetics Of Surufatinib
A Phase 1 Study To Assess The Effect Of Hepatic Impairment On The Pharmacokinetics Of Surufatinib
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics of Oral Epetraborole Tablets in Adult Subjects With Varying Degrees of Renal Function
A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics of Oral Epetraborole Tablets in Adult Subjects With Varying Degrees of Renal Function
Enrollment Status: Completed
Publish Date: July 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function
A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function
Enrollment Status: Completed
Publish Date: June 23, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function
A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Multi-Center Open-label Investigation to Assess the Pharmacokinetics, Safety and Tolerability of DM199 in Patients With Diabetes Mellitus and Chronic Kidney Disease
A Multi-Center Open-label Investigation to Assess the Pharmacokinetics, Safety and Tolerability of DM199 in Patients With Diabetes Mellitus and Chronic Kidney Disease
Enrollment Status: Completed
Publish Date: September 13, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, 2-Part, Open-Label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects
A Phase 1, 2-Part, Open-Label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects
Enrollment Status: Completed
Publish Date: August 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Enrollment Status: Completed
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function
An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Single-dose, Multicenter, Parallel Group Study to Assess the Pharmacokinetics and Safety of Alpelisib (BYL719) in Subjects With Hepatic Impairment Compared to Matched Healthy Control Subjects.
A Phase 1, Open-label, Single-dose, Multicenter, Parallel Group Study to Assess the Pharmacokinetics and Safety of Alpelisib (BYL719) in Subjects With Hepatic Impairment Compared to Matched Healthy Control Subjects.
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Multi-center, Single-dose Study to Evaluate the Pharmacokinetics of ABL001 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
A Phase I, Open-label, Multi-center, Single-dose Study to Evaluate the Pharmacokinetics of ABL001 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment
A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment
Enrollment Status: Terminated
Publish Date: September 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
Enrollment Status: Completed
Publish Date: May 20, 2019
Intervention Type: Drug
Study Phase: Phase 1
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects
A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects
Enrollment Status: Completed
Publish Date: August 09, 2018
Intervention Type: Drug, Other
Study Phase: Phase 1
Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
Enrollment Status: Withdrawn
Publish Date: June 28, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of the Effect of Meals With Various Amounts of Fat Given Immediately After Dosing on the Pharmacokinetics of an Oral Testosterone Undecanoate
A Phase 2 Study of the Effect of Meals With Various Amounts of Fat Given Immediately After Dosing on the Pharmacokinetics of an Oral Testosterone Undecanoate
Enrollment Status: Completed
Publish Date: May 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
Single-dose Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
Single-dose Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
Enrollment Status: Withdrawn
Publish Date: February 06, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 32 Less Clinical Trials

111 Total Publications

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment.
Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment.
Journal: Journal of clinical pharmacology
Published: April 04, 2025
Similar Doctors
Expertise in
34
conditions
Dr. Mark A. Lagatta
Nephrology
Expertise in
34
conditions
Dr. Mark A. Lagatta
Nephrology

Nephrology Associates Of Central Florida PA

4100 Metric Dr Ste 200, 
Winter Park, FL 
 (9.6 miles away)
407-681-8720
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Lagatta is a Nephrologist in Winter Park, Florida. Dr. Lagatta is highly rated in 34 conditions, according to our data. His top areas of expertise are Acute Kidney Failure, Chronic Kidney Disease, End-Stage Renal Disease (ESRD), and Necrosis. Dr. Lagatta is currently accepting new patients.

Expertise in
11
conditions
Dr. Hasan Shahab
Nephrology
Expertise in
11
conditions
Dr. Hasan Shahab
Nephrology

Nephrology Partners Of Central Florida LLC

10960 Dylan Loren Cir, 
Orlando, FL 
 (9.6 miles away)
407-420-7952
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hasan Shahab is a Nephrologist in Orlando, Florida. Dr. Shahab is highly rated in 11 conditions, according to our data. His top areas of expertise are Acute Kidney Failure, Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Necrosis, and Endoscopy.

Expertise in
13
conditions
Dr. Jorge Larranaga
Nephrology
Expertise in
13
conditions
Dr. Jorge Larranaga
Nephrology

Nephrology Associates Of Central Florida

1101 N Central Ave, 
Kissimmee, FL 
 (13.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jorge Larranaga is a Nephrologist in Kissimmee, Florida. Dr. Larranaga is highly rated in 13 conditions, according to our data. His top areas of expertise are End-Stage Renal Disease (ESRD), Acute Kidney Failure, Chronic Kidney Disease, and Necrosis. Dr. Larranaga is currently accepting new patients.

Frequently Asked Questions about Dr. Thomas Marbury

How do I make an appointment with Dr. Thomas Marbury?

You can book an appointment with Dr. Thomas Marbury by calling their office at 407-240-7878. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas Marbury a top-rated expert for Chronic Kidney Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas Marbury is classified as an Distinguished expert for Chronic Kidney Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas Marbury specialize in?

While Dr. Thomas Marbury is a Nephrology, they have specific expertise in Chronic Kidney Disease, End-Stage Renal Disease (ESRD), and Low Sodium Level. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Nephrology.

Does Dr. Thomas Marbury participate in research or clinical trials?

Yes. Dr. Thomas Marbury has published 111 articles and abstracts on conditions like Chronic Kidney Disease. You can view a list of Dr. Thomas Marbury's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas Marbury accept my insurance?

Dr. Thomas Marbury accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 407-240-7878 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marbury's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile